Fingolimod
 | |
 | |
| Klinički podaci | |
|---|---|
| Drugs.com | Monografija |
| Način primene | Oralno |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 6-9 dana |
| Identifikatori | |
| CAS broj | 162359-55-9  |
| ATC kod | L04AA27 (WHO) |
| PubChem | CID 107970 |
| DrugBank | DB08868 |
| ChemSpider | 97087 |
| ChEBI | CHEBI:63115 |
| ChEMBL | CHEMBL314854 |
| Hemijski podaci | |
| Formula | C19H33NO2 |
| Molarna masa | 307,471 |
| |
| |
| Fizički podaci | |
| Tačka ključanja | 4.794 °C (8.661 °F) |
Fingolimod je organsko jedinjenje, koje sadrži 19 atoma ugljenika i ima molekulsku masu od 307,471 Da.[1][2][3][4][5]
Osobine
[уреди | уреди извор]| Osobina | Vrednost |
|---|---|
| Broj akceptora vodonika | 3 |
| Broj donora vodonika | 3 |
| Broj rotacionih veza | 12 |
| Particioni koeficijent[6] (ALogP) | 4,2 |
| Rastvorljivost[7] (logS, log(mol/L)) | -6,1 |
| Polarna površina[8] (PSA, Å2) | 66,5 |
Reference
[уреди | уреди извор]- ^ An X, Kezuka T, Usui Y, Matsunaga Y, Matsuda R, Yamakawa N, Goto H: Suppression of Experimental Autoimmune Optic Neuritis by the Novel Agent Fingolimod. J Neuroophthalmol. 2013 Apr 19. PMID 23609767
- ^ Ali R, Nicholas RS, Muraro PA: Drugs in Development for Relapsing Multiple Sclerosis. Drugs. 2013 Apr 23. PMID 23609782
- ^ http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cc9e1c8c-0e2b-44e2-878b-27057f786be9nlm34090-1
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
- ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
- ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.
Literatura
[уреди | уреди извор]- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
[уреди | уреди извор]
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Credit:
(see original file).
